Latham & Watkins Advises Arcus Biosciences on US$250 Million Public Offering of Common Stock
Arcus Biosciences (NYSE: RCUS) priced a public offering of 14.3 million shares at $17.50 each, raising $250 million. The company granted underwriters a 30-day option to buy 2.1 million more shares. The offering is expected to close on October 23, 2026. Latham & Watkins LLP advised Arcus.
How this was made
The 30-second read
Why it matters
The raise provides cash for pipeline advancement but introduces dilution, likely pressuring the share price until milestones are achieved.
Market read
Primary disclosure of a material equity raise for a US‑listed biotech, directly relevant for traders monitoring dilution risk.
What to watch
Potential strategic partnership or pipeline milestones that could be funded by the proceeds are not disclosed.
Background
Arcus Biosciences is a late‑clinical‑stage biopharma focused on cancer and immune diseases. The offering is underwritten and includes a 30‑day option for additional shares.
Ticker impact
Arcus Biosciences announced pricing of a $250 million public offering of 14.3 million shares at $17.50 each.
downward pressure as the market prices in dilution from the new shares
A $250 M primary offering is material for a late‑stage biotech; investors typically react negatively to dilution.
Market effects
Biotech sector may see modest sell‑off as investors reassess dilution risk across peers.
US biotech market may experience slight downward bias; no broader regional effect.
Limited to investors tracking US‑listed biotech capital raises.
Counterpoint
If the capital is deployed to accelerate late‑stage trials, the long‑term upside could outweigh short‑term dilution.
Key entities
- companyArcus Biosciences, Inc.
Issuer of the $250 M public offering.
- law_firmLatham & Watkins LLP
Legal advisor to Arcus on the offering.
